Rituximab-IgG2 is a phagocytic enhancer in antibody-based immunotherapy of B-cell lymphoma by altering CD47 expression
O. T. P. Nguyen, S. Lara, G. Ferro, M. Peipp, S. Kleinau
This study shows RTX-IgG2 enhances phagocytosis of B-cell lymphoma cells by reducing CD47 expression and promoting apoptosis, improving the efficacy of antibody-based therapies.
bioRxiv · Jun 18, 2024Immunology